Lilly's Humalog -- First New Insulin in 14 Years -- Wins Approval of European Union Medical Product Licensing Agency (01May1996)
AVENTIS PHARMACEUTICALS’ LANTUS® (insulin glargine [rDNA origin] injection) APPROVED BY FDA FOR TREATMENT OF DIABETES (24Apr2000)
FDA Approves First Ever Inhaled Insulin Combination Product for Treatment of Diabetes (27Jan2006)
FDA Approves New Treatment [Januvia (sitagliptin phosphate)] for Diabetes (17Oct2006)
Study Tests Anti-Inflammatory Drug for Poorly Controlled Type 2 Diabetes (03Feb2009)
FDA Approves New Drug Treatment [Onglyza (saxagliptin)] for Type 2 Diabetes (31Jul2009)
FDA Approves New Treatment [Victoza (liraglutide)] for Type 2 Diabetes (25Jan2010)
Questions and Answers - Safety Requirements for Victoza (liraglutide) (25Jan2010)
FDA significantly restricts access to the diabetes drug Avandia (23Sep2010)
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET (15Nov2010)
Insulin Therapy for Hospitalized Patients Should Not Be Abandoned (16Feb2011)
FDA approves new treatment [Tradjenta (linagliptin)] for Type 2 diabetes (02May2011)
Update on ongoing European review of pioglitazone-containing medicines (09Jun2011)
FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer (15Jun2011)
Medical Societies Respond to the FDA’s Safety Announcement on the Use of the Diabetes Medication Actos (pioglitazone) (16Jun2011)
FDA Advisory Committee makes recommendation on investigational compound dapagliflozin (20Jul2011)
FDA approves combination therapy Juvisync (07Oct2011)
FDA Approves Merck's JUVISYNC™ (sitagliptin and simvastatin) Tablets, a Once-Daily Therapy for Patients with Type 2 Diabetes Who Need to Lower Blood Sugar and Cholesterol, Known Risk Factors for Cardiovascular Disease (07Oct2011)
BYETTA® Approved for Use with Insulin Glargine in the U.S. (19Oct2011)
Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin (08Nov2011)
U.S. Food and Drug Administration (FDA) Delays Review of Takeda's Investigational Type 2 Diabetes Therapies, Alogliptin and Alogliptin/Pioglitazone (18Nov2011)
Takeda Submits New Drug Application in the U.S. for Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin/Metformin (23Nov2011)
Lilly Announces First and Only International, Prospective Observational Study Designed to Understand Barriers to Progression of Insulin Treatment (01Dec2011)
Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings (07Dec2011)
JDRF to Support ViaCyte's Development of Innovative Encapsulated Beta Cell Replacement Therapy for Diabetes (13Dec2011)
FDA Approves BYDUREON™ -- The First and Only Once-Weekly Treatment for Type 2 Diabetes (27Jan2012)
FDA approves Jentadueto™ (linagliptin/metformin hydrochloride) tablets for the treatment of adult patients with type 2 diabetes (30Jan2012)
FDA Approves JANUMET® XR (sitagliptin and metformin HCl extended-release) for Type 2 Diabetes, Offering the Powerful Efficacy of JANUMET® (sitagliptin/metformin HCl) Now Available with Once-Daily Convenience (02Feb2012)
FDA announces safety changes in labeling for some cholesterol-lowering drugs (28Feb2012)
Public Citizen to FDA: Pull Diabetes Drug Victoza From Market Immediately (19Apr2012)
FORXIGA (dapagliflozin) receives positive CHMP opinion in the European Union for the treatment of type 2 diabetes (20Apr2012)
Study Finds No Increased Heart, Cancer Risk from Daily Insulin Glargine Use (11Jun2012)
Anti-Inflammatory Drug, Used for Decades, Now Found to Lower Blood Glucose Levels in People with Type 2 Diabetes (11Jun2012)
Studies Find No Increase in Cancer Risk from Insulin Glargine (11Jun2012)
Global survey finds one in four type 2 diabetes patients do not take basal insulin as prescribed and more than a third suffer from hypoglycaemia (12Jun2012)
FDA approves first generic Actos to treat type 2 diabetes (17Aug2012)
FDA approves three new drug treatments for type 2 diabetes (25Jan2013)
Novo Nordisk receives Complete Response Letter in the US for Tresiba and Ryzodeg (10Feb2013)
FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes (14Mar2013)
FDA approves Invokana to treat type 2 diabetes (29Mar2013)
American Diabetes Association Calls for Independent Review of Incretin Therapy (10Jun2013)
FDA alerts companies to stop illegal sale of treatments for diabetes (23Jul2013)
FDA alerts consumers of undeclared drug ingredients in over-the-counter diabetes product (23Jul2013)
American Association of Clinical Endocrinologists Consensus Statement On Diabetes and Cancer (20Aug2013)
FDA requires removal of certain restrictions on the diabetes drug Avandia (25Nov2013)
FDA approves Farxiga to treat type 2 diabetes (08Jan2014)
FDA to review heart failure risk with diabetes drug saxagliptin (marketed as Onglyza and Kombiglyze XR) (11Feb2014)
FDA Advisory Committee Recommends Approval of AFREZZA(R), MannKind Corporation's Investigational Drug to Treat Diabetes (01Apr2014)
GSK receives US approval for once-weekly type 2 diabetes treatment, TanzeumTM (albiglutide) (15Apr2014)
FDA approves Avandia (rosiglitazone) label update, lifts restrictions on patient access (07May2014)
FDA approves Afrezza to treat diabetes (27Jun2014)
FDA approves Jardiance to treat type 2 diabetes (01Aug2014)
Long-acting insulin is safer, more effective for patients with Type 1 diabetes (01Oct2014)
FDA approves weight-management drug Saxenda (23Dec2014)
Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S. (03Feb2015)
FDA approves two new drug treatments for diabetes mellitus (25Sep2015)
FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes (16Dec2015)
MannKind Corporation Announces Termination of License and Collaboration Agreement With Sanofi (07Jan2016)
Metformin-containing Drugs: Revised Warnings for Certain Patients With Reduced Kidney Function (08Apr2016)
FDA approves Adlyxin to treat type 2 diabetes (28Jul2016)
Lilly Announces Program to Provide Insulin at Discounted Prices (13Dec2016)
U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes (12Dec2016)
FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) (22May2017)
Novo Nordisk Receives FDA Approval for Fiasp, a New Fast-Acting Mealtime Insulin (29Sep2017)
FDA approves Admelog, the first short-acting "follow-on" insulin product to treat diabetes (11Dec2017)
American Diabetes Association® Releases Long- and Short-Term Public Policy Recommendations for Improving Insulin Affordability (24May2018)
ADA, JDRF and Helmsley Charitable Trust Announce Funding of Quantitative Analysis of Insulin Purchased from Pharmacies in the U.S. (11Oct2018)
Lilly to Introduce Lower-Priced Insulin (04Mar2019)
Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s continued efforts to bring competition to the insulin market to lower prices and expand access (02Apr2019)
FDA approves new treatment for pediatric patients with type 2 diabetes
(17Jun2019)
FDA approves first oral GLP-1 treatment for type 2 diabetes (20Sep2019)
Statement from Acting FDA Commissioner Adm. Brett P. Giroir, M.D., on efforts to help make development of biosimilar and interchangeable insulin products
(25Nov2019)
Statement from Janet Woodcock, M.D., director of FDA’s Center for Drug Evaluation and Research, on impurities found in diabetes drugs outside the U.S.
(05Dec2019)
FDA Works to Ensure Smooth Regulatory Transition of Insulin and Other Biological Products
(20Feb2020)
FDA Proposes Broad Approach for Conducting Safety Trials for Type 2 Diabetes Medications
(09Mar2020)
